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As part of human evolutionary development, many human organ systems have innate mechanisms to
adapt to increased “work demand” or stress. This reserve capacity can be informative and is used
commonly in cardiology to assess cardiac function (e.g., treadmill test). Similarly, the kidney possesses
reserve capacity, which can be demonstrated in at least 2 of the following renal domains: glomerular and
tubular. When appropriate stimulants are used, healthy patients with intact kidneys can signiﬁcantly increase their glomerular ﬁltration rate and their tubular secretion. This approach has been used to develop
diagnostics for the assessment of renal function. This article reviews both glomerular and tubular kidney
stress tests and their respective diagnostic utility.
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s part of human evolutionary development, many
human organ systems have innate mechanisms to
adapt to increased “work demand” or stress. At rest,
organ systems operate at baseline capacity, and this
capacity can be increased to a certain maximum capacity. A familiar example of this concept is cardiac
function. In a healthy person at rest, cardiac output is
approximately 5.0 liters/min. However, when a healthy
person exercises, the cardiac output can double or even
triple. Similarly, the kidney has reserve capacity of its
multiple physiological functions (Figure 1). The ability
to test the reserve of an organ system is often an
excellent diagnostic tool to uncover subclinical disease
(e.g., treadmill test). Similarly, stress testing of the
kidney appears to generate insights into the presence
or absence of kidney disease and parenchymal loss due
to injury and potentially ﬁbrosis. The 2 main domains
of kidney stress testing are glomerular and tubular. In a
healthy kidney, these 2 components of the nephron
work in concert. However, when the kidney is diseased
or injured, the glomerular and tubular function may be
affected equally, or their form and functional capacity
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may diverge. An assessment of both glomerular and
tubular function may be more informative than just 1
of these domains. Glomerular reserve testing has been
well established but is used infrequently in routine
clinical care. Tubular function diagnostic testing is
relatively new and in its clinical “infancy.” However,
tubular assessment appears to hold signiﬁcant promise
for the assessment of both chronic and acute kidney
disease.
Renal Functional Reserve–Glomerular
Because of the common use of estimated glomerular
ﬁltration rate (GFR) equations, there is a tendency for
non-nephrologists to think that the GFR is a constant.
In fact, the actual GFR changes throughout the day,
particularly after meals, based on physiological needs.1
One of the kidney’s primary roles is to effectively
remove nitrogenous waste, and as a consequence, the
consumption and metabolism of protein results in an
increase in GFR.2 GFR can also be increased through
other mechanisms that work along the protein metabolic pathway. For instance, an i.v. infusion of amino
acids will result in an increase in GFR.3 This increase in
GFR over baseline GFR is known as renal functional
reserve–glomerular (RFR-G).4 Protein ingestion,
particularly red meat, is a potent stimulant for
increasing GFR, and the teleologic explanation is likely
related to an adaptive response to increased protein in
the diet.5
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seen in patients who donate a kidney; despite a halving
of their nephron mass, their serum creatinine and
calculated eGFR are “normal.”10 Therefore, when renal
disease becomes apparent due to an elevated serum
creatinine, this occurs only after the residual nephrons
can no longer compensate for the functional loss
(Figure 3).8
Renal Functional Reserve (RFR-G)

Figure 1. Comparison of stressors in the heart and kidney. C-R,
cardiorenal.

Bosch and colleagues ﬁrst described glomerular
functional reserve (RFR-G) in 1983.4 In this seminal
paper, Bosch and colleagues demonstrated that the
consumption of protein, not carbohydrates or fat, results in a substantial increase in GFR in patients with
healthy kidneys. Multiple subsequent studies have
conﬁrmed these ﬁndings. The clinical implications of
RFR-G will be reviewed.
Baseline (Unstressed) GFR

GFR is normally utilized as a surrogate of kidney
function in healthy subjects as well as in patients with
kidney disease. Studies in healthy subjects under the
age of 50 have identiﬁed the average baseline normal
values of GFR to be between 100 and 130 ml/min per
1.73 m2.6 Evaluation of population-wide “normal”
values is useful, but the concept of “normal” GFR in
the single individual is more nuanced. It is important to
recognize that a person’s GFR at any given point in
time will vary in relation to the physiological demands
of dietary and hemodynamic conditions. Baseline value
for GFR (bGFR) also depends on age, sex, and body
size, with considerable variation among healthy individuals. Overall, the average daily GFR is remarkably
stable over years, although there is an age-related
decline in GFR physiologically by 0.8 ml/min per
1.73 m2 per year, after the age of 30 years.6,7
In general, serum creatinine tends to remain relatively normal even in the presence of kidney damage,
until approximately 50% of nephrons are lost or
simply when bGFR approaches 60 ml/min per 1.73 m2
(Figure 2).8 For this reason serum creatinine cannot be
considered an accurate marker of renal function when
GFR is above 60 ml/min per 1.73 m2. Similarly, GFR
estimation (eGFR) by creatinine-derived equations (e.g.,
MDRD9) cannot be considered a sensitive index for
early detection of renal disease during the early phases
of parenchymal damage. A good example of this can be
58

Normal subjects display a signiﬁcant increase in GFR 1
or 2 hours after an acute protein load (1–1.2 g/kg) over
their baseline GFR. The difference between peak or
“maximum” GFR (maxGFR) and baseline GFR describes
the renal functional reserve of glomerular function
(RFR-G). Fliser and colleagues11 compared the baseline
and maxGFR in young and elderly healthy subjects and
found that RFR was signiﬁcantly lower in elderly than
in young healthy individuals while virtually all baseline GFR values of elderly were within the reference
range. The renal reserve as assessed by RFR-G is a
measure of the kidney’s capacity to increase GFR by a
combination of nephron recruitment and increases in
renal blood ﬂow coupled with hyperﬁltration.12–15
The stimulus to tap into this reserve capacity can
arise from adaptive physiological needs like pregnancy
or the presence of a solitary kidney. Utilization of RFR
in non-disease states is best illustrated by pregnancy.
In pregnancy, GFR signiﬁcantly increases during each
trimester, such that there is a signiﬁcant rise in bGFR
from ﬁrst to last trimester. Studies done on normal
pregnant women in each trimester have shown a progressive increase of baseline GFR with a parallel
reduction of RFR due to its progressive utilization.13
MaxGFR in normal pregnant women, however, does
not change. However, pathological states can also
initiate processes that increase GFR above the normal
baseline. Primary hyperﬁltration in kidney disease has
been shown in patients with diabetes mellitus, polycystic kidney disease, secondary focal segmental

Figure 2. Relationship between glomerular ﬁltration rate (GFR) and
serum creatinine changes. RFR-G, renal functional reserve–glomerular.
Kidney International Reports (2016) 1, 57–63
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Figure 3. Variation in baseline glomerular ﬁltration rate (GFR).

glomerulosclerosis, sickle cell anemia, high-altitude
renal syndrome, obesity, hypertension, nephrotic
syndromes, and glomerulonephritis.16 In physiological
states of diminished RFR, the observed hyperﬁltration
is likely due to recruitment of more nephron units,
whereas in pathological states, hyperﬁltration is probably due to an increase in single nephron ﬁltration
fraction. This, in part, is the basis of angiotensin II
blockade in chronic kidney disease (CKD), and is often
demonstrable by a drop in GFR when angiotensinconverting enzyme inhibitors are given to patients
with CKD.
A current limitation on the use of RFR-G assessment
is that these assessments have not been conducted in
large cross-sectional cohorts, thus the population
variability of the RFR response is not known. Several
investigators have estimated RFR by measuring the
difference between protein-stimulated GFR and baseline GFR after a protein load.4 In a separate study,17
Bosch and colleagues demonstrated the estimation of
RFR by a short-term oral protein loading method. De
Nicola and colleagues18 demonstrated that the estimation of RFR can be assessed by amino acid infusion.
Numerous mechanisms have been hypothesized for
the increase in GFR after protein load. In their study,
Woods and colleagues19 hypothesized that protein
loading increases GFR because digested protein raises
plasma amino acid levels, which are then ﬁltered at the
glomerulus, thereby stimulating proximal tubular absorption. In addition, ﬁltered amino acids change the
sensitivity of macula densa sensing mechanisms,
causing release of nitric oxide and prostaglandins
locally resulting in vasodilation, increasing renal blood
ﬂow and GFR. In our own laboratory we analyzed the
response to acute protein loading, and we detected an
increase in GFR proportional to an increase in renal
blood ﬂow with a constant of ﬁltration fraction. This
observation seems to support the hypothesis that an
Kidney International Reports (2016) 1, 57–63
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overall increase in blood ﬂow is the main mechanism
rather than a temporary hemodynamic perturbation in
the afferent and efferent tone and equilibrium
(C. Ronco and colleagues, unpublished data).
Stress testing with a protein load is the deﬁnitive
way to assess for the loss of RFR-G, but the signiﬁcance
of renal reserve is not just a diagnostic consideration. It
is important to recognize that the loss of renal reserve
may also manifest as a loss in autoregulation capacity in
the kidney. This loss of autoregulation may increase
the vulnerability of those patients with CKD to volume
depletion and certain nephrotoxins (e.g., nonsteroidal
anti-inﬂammatory drugs). Population studies suggest
that increased creatinine variability, which could be
due to the loss of autoregulation, predicts progression
to end-stage renal disease.20
Kidney Stress Testing of GFR in Clinical
Practice and Future Research
Assuming RFR-G represents the difference between
maximal ﬁltration capacity of the kidney (maxGFR) and
the baseline GFR (bGFR), a protein load is the basis of a
kidney stress test forcing the kidneys to utilize the
entire ﬁltration capacity. This technique can be used to
“reveal” subclinical kidney disease. MaxGFR and bGFR
assessment with protein loading has been extensively
studied and can be used in the clinic to assess RFR-G in
patients with kidney disease.4,8,13,14 Because dietary
protein raises GFR, establishing bGFR is important
when attempting to assess RFR-G; developing standardized protocols to accomplish this is an important
research recommendation. There is another approach
that would allow single GFR assessment instead of
having to conduct a baseline and a stimulated stress
test. In this approach, the maxGFR would be assessed
among healthy patients across a wide age range, ethnic
range, and in both genders. Once these data were
known, then normative values could be determined for
maxGFR. These data would be used for diagnostic
purposes for patients who underwent a kidney stress
test to achieve maxGFR. Those patients who could not
achieve the appropriate maxGFR adjusted for age,
gender, and race could be referred for further work-up.
As part of a future research plan, the safety of
repeated protein loading in patients with CKD should
also be assessed. Since protein is a stimulant for GFR,
the effects of repeated protein loading in patients with
CKD is unknown. The exposure of repeated high levels
of protein in patients with CKD might be deleterious,
but might also “condition” the kidney as well and
stimulate restorative or protective effects—this concept
should be studied further.
The idea of assessing renal reserve has been present
for decades, but is infrequently used in clinical
59
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practice, whereas the cardiac stress test is used
routinely. Why is this the case? In our view, the simple
reason is that cardiologists perceive that they can
intervene on patients with diminished cardiac reserve
(e.g., heart failure treatment), whereas the nephrology
community may not feel that an intervention is available, and therefore may be unwilling to perform an
extra test. We hypothesize that patients with loss of
renal reserve are at risk for CKD. Future trials should
assess whether early identiﬁcation of diminished renal
reserve can reliably predict the risk of progression to
CKD. If this can be shown, early screening of renal
reserve may prompt early intervention and forestall the
development of CKD.
Tubular Function Assessment in Kidney Disease
The renal tubule portion of the nephron is tasked with
an enormous portfolio of responsibilities. Chief among
those chores are the handling of electrolytes, water,
and amino acids, catabolism of various proteins, and
the active secretion of endogenous and exogenous
acids. Tubular function assessment may be more
informative than glomerular reserve in patients who
already have advanced kidney disease. When patients
do not have obvious kidney disease, the loss of
glomerular reserve (RFR-G) can be an indicator of loss
of nephron mass.8 However, once a patient has kidney
injury or disease, glomerular reserve is already substantially reduced and therefore is less informative.
In patients with decreased GFR, tubular function
appears to be more variable. One reason for this
observation may be due to renal ﬁbrosis. During the
assessment of kidney disease by tissue biopsy, the
level of interstitial ﬁbrosis is one of the strongest predictors of renal survival.21,22 Interstitial ﬁbrosis can
represent scarred tubules that are ﬁbrosed, or the
secretion of matrix that ﬁlls in between the nephrons,
or both of these. However, because CKD is generally
marked by a reduction of kidney size, this makes the
possibility of “extra” matrix an unlikely sole explanation for ﬁbrosis (an exception to this would be
multiple myeloma). In most forms of kidney disease,
the kidneys shrink and become more echogenic over
time. Based on this observation, we believe that it is
more likely that diseased tubules are replaced by matrix and ﬁbrosis. In order to test the notion that tubular
function may identify patients who are at increased
risk for worse outcomes, various studies in patients
with both acute and chronic kidney disease have been
conducted to determine the utility of tubular secretion
capacity to predict outcomes.23,24
Different aspects of tubular function can be interrogated in various ways depending on what feature of
tubular function is being assessed. For instance, the
60

tubule’s capacity to secrete acid or sodium can be
assessed via acid or salt loading. The tubule’s concentrating capacity can be assessed via water deprivation
or exogenous administration of desmopressin (DDAVP).
Among these different techniques, thus far the primary
methodology to assess tubular functional capacity in
patients with kidney disease has been via tubular
secretion of either creatinine or an exogenous drug
(e.g., furosemide).
Tubular Function Assessment in CKD
The ﬁrst studies of tubular functional capacity in patients
with CKD utilized the difference between creatinine
clearance and inulin clearance as an assessment of tubular
function. Herrera and colleagues24 developed an elegant
study to demonstrate the potential use of tubular secretion. In this study, the investigators took the following 3
cohorts of patients: normal, renal allograft donors (uninephrectomized), and CKD. In these subjects, baseline
creatinine clearance and inulin-based GFR were
measured and then reassessed after a protein meal. They
found that both healthy patients and patients with CKD
were able to increase their inulin-measured GFR in
response to a protein meal; as expected, healthy patients
could increase their GFR after stimulation much more
than CKD patients. Similarly, healthy patients were able
to increase their tubular secretion of creatinine (TScr),
but CKD patients were unable to increase their TScr.
When all 3 groups of patients were compared, uninephrectomized patients were able to increase their
TScr (but to a lesser degree than normal healthy subjects),
while CKD patients were unable to increase their TScr.
These data are consistent with previous studies that show
that patients with CKD maintain some glomerular renal
reserve at all levels of baseline GFR.8 In addition, this
study demonstrated that CKD patients likely operate at
near their maximum TScr, and thus are less able to increase their TScr when challenged with a protein meal.
In a second trial, this same group of investigators
assessed TScr by infusing i.v. creatinine into normal
subjects and kidney transplant recipients.25 They found
that creatinine infusion did not increase GFR, and that
an infusion of i.v. creatinine resulted in an increased
TScr in healthy patients, but not in kidney transplant
recipients. Thus, a tubular functional assessment with a
challenge of i.v. creatinine had the capacity to reveal the
subjects with decreased nephron mass who otherwise
had normal serum creatinine levels.
In aggregate, preliminary studies suggest that
tubular stress tests that measure the secretory capacity
of the renal tubule are informative and predictive of
outcomes.23–26 However, it should be noted that
tubular stress tests remain research tools and have not
yet been deployed into the clinic for CKD.
Kidney International Reports (2016) 1, 57–63

LS Chawla and C Ronco: Renal Stress Testing in the Assessment of Kidney Disease

Tubular Assessment in Acute Kidney Injury
The aforementioned studies in CKD used creatinine
secretion to assess tubular functional assessment. In
patients with acute kidney injury (AKI), many factors,
including lack of steady state, increased catabolism,
and concurrent medications that interfere with creatinine secretion, preclude the use of TScr as a reliable
measure of tubular secretion. One approach uses i.v.
furosemide to assess tubular function. Furosemide, a
loop diuretic, has pharmacokinetic properties that
make it an appealing functional tool. In contrast to
other drugs cleared by the kidney, furosemide is not
effectively ﬁltered by the glomerulus. As an organic
acid, furosemide is tightly bound to albumin and gains
access to the tubular lumen by active secretion via the
human organic anion transporter system in the proximal convoluted tubule.27,28 Once in the tubular lumen,
furosemide blocks luminal cation–chloride cotransport
throughout the thick ascending limb of Henle, thereby
preventing sodium reabsorption and resulting in
natriuresis and increased urine ﬂow.29–31 Based on
these properties, furosemide-induced increases in urine
output represent a methodology to assess the integrity
of the renal tubular function in the setting of AKI. This
methodology was developed by Chawla and colleagues23 and is referred to as the furosemide stress test
(FST).
The FST has been prospectively assessed in a single
cohort study of critically ill patients with AKI and was
found to have good diagnostic performance. In that
study, Chawla and colleagues23 administered a standard dose of i.v. furosemide (1.0–1.5 mg/kg) to critically ill patients with Kidney Disease: Improving
Global Outcomes (KDIGO) stage I or stage II AKI and
then assessed the urine output response. This study
showed that the 2-hour urine output response to a
furosemide challenge was able to predict progression to
KDIGO stage III within 14 days with a receiver operating characteristic area under the curve of 0.87
(SE, 0.05). At a cutoff of 200 cm3 at 2 hours, the
sensitivity and speciﬁcity of the FST were 87.1% and
84.1%, respectively.23 In a follow-up study of the same
cohort, the same research group showed that FST
performed better than known AKI biomarkers.
Importantly, the follow-up study demonstrated that
the FST performance improves when utilized in patients with increased levels of AKI biomarkers.32 These
data suggest that the combination of AKI biomarkers
with tubular functional assessment is informative, and
can be used at the bedside to assist clinicians in
assessing the severity of AKI. It remains unclear
whether the FST reveals the severity of AKI, or the loss
of tubular functional capacity. An important caveat to
the FST is that the subject must be euvolemic for the
Kidney International Reports (2016) 1, 57–63
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test to be safe and valid, and any volume losses induced
by the diuresis should be replaced.
A version of the FST has also been analyzed in patients
with advanced-stage AKI requiring renal replacement
therapy to determine whether a standardized furosemide
challenge can predict renal recovery. van der Voort and
colleagues reported that a standardized 4-hour infusion
of furosemide was also an excellent predictor of renal
recovery.26,33 This analysis was a post hoc assessment of a
randomized clinical trial, which compared a 4-hour
infusion of furosemide to placebo as an intervention to
promote renal recovery in patients who are on continuous renal replacement therapy. In this post hoc analysis,
the authors assessed the intervention arm of the trial (i.e.,
the patients randomized to furosemide) and found that
the mean urine output was much higher in patients
destined to recover (654 ml vs. 48 ml, P ¼ 0.007) and had
a diagnostic performance receiver operating characteristic area under the curve of 0.84. These 2 studies
demonstrate that the urine output response to furosemide is informative about renal tubular function
throughout the phases of AKI (progression and recovery). Another advantage of the FST is that it does not just
measure the tubule’s secretion capacity, but is actually
an assessment of integrated renal function34 (Figure 4). In
order for furosemide to increase urine output, furosemide must be actively secreted into the proximal lumen,
and the thick ascending limb, luminal patency, and
collecting duct function must all be intact.35 Because the
FST requires an intact nephron for full function, the FST
does not readily identify the location of the defect in
cases in which the FST response is poor.
The aforementioned studies of FST are of modest size
and are currently undergoing larger-scale validation
(NCT 01275729). However, the FST is based on the
bedside practice of many clinicians, which involves
challenging patients with a loop diuretic and assessing
the clinical response. The FST, as currently devised, is
simply a framework around this common bedside
practice. The FST is also being assessed by the 0 by 25

Figure 4. Furosemide urinary response tests tubular integrity. TAL,
thick ascending limb.
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initiative spearheaded by the International Society of
Nephrology. In an austere medical environment, simple
diagnostic tools like serum urea and creatinine are not
readily available. Thus, the use of FST in euvolemic
patients with oliguria may allow a thoughtful way to
triage patients who may need more advanced care.
Because furosemide is inexpensive and available
worldwide, this physiological assessment may allow for
broader use of this diagnostic approach.
Summary
Kidney stress testing can be accomplished by assessing
glomerular and tubular domains. These assessments are
safe and relatively inexpensive and can be done at the
bedside or in the clinic. Importantly, these assessments
have been shown to be informative in both acute and
chronic kidney disease. However, neither of these
stress tests is currently used routinely at the bedside or
the clinic. Assessment of RFR-G can and, in the opinion
of these authors, should be used to reveal the loss of
RFR in patients at risk for kidney disease. Tubular
functional testing has been less developed; early
studies demonstrate good diagnostic performance, but
large validation studies are still needed. Because
tubular testing may have the capacity to assess multiple
anatomic domains of the nephron, we believe that
noninvasive kidney stress testing may allow clinicians
to phenotype, prognosticate, and better follow patients
with kidney disease. Further research into the appropriate use of these diagnostic techniques is warranted.
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